PETALING JAYA: Pharmaniaga Bhd
’s net profit in its third quarter ended Sept 30 more than tripled to RM26.9mil from RM7.5mil a year earlier, as higher insulin sales and interest savings helped lift earnings.
In a statement, the group said quarterly revenue rose 0.7% to RM1.01bil, mainly on higher insulin sales, while partial repayment of borrowings generated RM3.2mil in interest savings.
For the nine months ended Sept 30, net profit rose 72% to RM72.2mil, while revenue increased 8.2% to RM3.23bil.
This was driven mainly by stronger demand in the concession segment.
Pharmaniaga declared a third interim dividend of 0.32 sen per share for financial year 2026 (FY26).
Managing director Datuk Zulkifli Jafar said: “Our key business divisions continued to demonstrate resilience and steady progress, supported by sustained demand, operational improvements and ongoing efforts to strengthen our market presence.”
Zulkifli said the increase in the Health Ministry’s allocation to RM47.7bil under Budget 2027, from RM46.5bil in 2026, would support the healthcare sector.
